|Chemical and physical data|
|Molar mass||366.343 g·mol−1|
|3D model (JSmol)|
HT-2157 (former development code SNAP-37889) is a drug which acts as a selective non-peptide antagonist for the receptor GAL-3, which is usually activated by the neuropeptide galanin. Blocking this receptor with HT-2157 produced increased serotonin release, as well as producing antidepressant and anxiolytic effects in animal studies, and it was also being researched for treatment of cognitive dysfunction. All human clinical trials were terminated due to safety concerns however, and new GAL-3 antagonists are now being sought instead.
- "pA2 Online". www.pa2online.org.
- Swanson, C. J.; Blackburn, T. P.; Zhang, X.; Zheng, K.; Xu, Z.-Q. D.; Hokfelt, T.; Wolinsky, T. D.; Konkel, M. J.; Chen, H.; Zhong, H.; Walker, M. W.; Craig, D. A.; Gerald, C. P. G.; Branchek, T. A. (2005). "Anxiolytic- and antidepressant-like profiles of the galanin-3 receptor (Gal3) antagonists SNAP 37889 and SNAP 398299". Proceedings of the National Academy of Sciences. 102 (48): 17489–17494. doi:10.1073/pnas.0508970102. PMC 1283534. PMID 16287967.
- US 8277842, Kaplan AP, "Enteric-coated HT-2157 compositions and methods of their use", published January 20, 2012
- "Dart NeuroScience LLC -- Scientific Advisory Board". www.dartneuroscience.com.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|